CIA-II is associated with lower-grade glioma survival and cell proliferation

BackgroundThe role of CIA-II has been clarified in several types of tumors; however, whether dysregulated CIA-II expression is also involved in the pathophysiology of lower-grade glioma (LGG) remains undisclosed. MethodsA comprehensive pan-cancer analysis of the expression patterns and prognostic significance of CIA-II in miscellaneous tumors was undertaken. Subsequently, a detailed bioinformatics analysis was executed to identify putative correlations between CIA-II expression and clinical features, prognosis, biological functions, immunological characteristics, genomic alterations, and chemotherapeutics in LGG. In vitro studies were implemented to examine the potential roles of CIA-II in LGG. ResultsCIA-II expression was found to be abnormally elevated in a variety of tumors, including LGG. Additionally, patients with LGG with higher CIA-II expression owned worse prognosis. Importantly, the results declared that CIA-II expression was an independent prognostic indicator for LGG. Moreover, the expression of CIA-II was tightly interrelated with immune cell infiltration, gene mutations, and chemotherapeutics in LGG. In vitro studies revealed that CIA-II was increased and strongly related to the cell proliferation in LGG. ConclusionCIA-II may be an independent prognostic factor and a serviceable therapeutic target in LGG.

Automated summary

This study found that CIA-II is highly expressed in various tumors, including lower-grade glioma (LGG), and higher CIA-II expression in LGG patients is associated with worse prognosis. Moreover, CIA-II expression is closely related to immune cell infiltration, gene mutations, and chemotherapeutics in LGG. In vitro studies also revealed that CIA-II is strongly associated with cell proliferation in LGG. Therefore, CIA-II may serve as an independent prognostic factor and a potential therapeutic target in LGG.